{"title": "Clene polishes tarnished ALS asset with long-term survival data", "author": "Nick Paul Taylor", "url": "https://www.fiercebiotech.com/biotech/clene-polishes-tarnished-als-asset-long-term-survival-data", "hostname": "fiercebiotech.com", "description": "Clene has shared another cut of long-term data from its phase 2 amyotrophic lateral sclerosis (ALS) trial. | Clene has shared another cut of long-term data from its phase 2 amyotrophic lateral sclerosis (ALS) trial. The open-label extension linked a gold nanocrystal suspension to improved survival, but, with setbacks including a primary endpoint miss hanging over it, Clene's share price remains in the basement.", "sitename": "FierceBiotech", "date": "2023-08-29", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Fierce 50 Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Subscribe Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Fierce 50 Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}